Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

被引：13

作者：

Griguolo, Gaia ^{[1
,2
]}

Dieci, Maria Vittoria ^{[1
,2
]}

Pare, Laia ^{[3
,4
]}

Miglietta, Federica ^{[1
,2
]}

Generali, Daniele Giulio ^{[5
]}

Frassoldati, Antonio ^{[6
]}

Cavanna, Luigi ^{[7
]}

Bisagni, Giancarlo ^{[8
]}

Piacentini, Federico ^{[9
]}

Tagliafico, Enrico ^{[10
]}

Cagossi, Katia ^{[11
]}

Ficarra, Guido ^{[12
]}

Prat, Aleix ^{[3
,4
]}

Conte, Pierfranco ^{[1
,2
]}

Guarneri, Valentina ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[2] Ist Oncol Veneto IOV IRCCS, Div Oncol 2, Padua, Italy

[3] Hosp Clin Barcelona, IDIBAPS, Div Oncol, Barcelona, Spain

[4] SOLTI Breast Canc Res Grp, Barcelona, Spain

[5] AO Ist Ospitalieri Cremona, Multidisciplinary Unit Breast Pathol, Cremona, Italy

[6] S Anna Univ Hosp, Dept Morphol Surg & Expt Med, Clin Oncol, Ferrara, Italy

[7] Piacenza Gen Hosp, Dept Hematol & Oncol, Oncol Unit, Piacenza, Italy

[8] Azienda Unita Sanit Locale IRCCS Reggio Emil, Dept Oncol & Adv Technol, Oncol Unit, Reggio Emilia, Italy

[9] Univ Hosp Modena, Dept Med & Surg Sci Children & Adults, Div Med Oncol, Modena, Italy

[10] Univ Modena & Reggio Emilia, Ctr Genome Res, Modena, Italy

[11] Ramazzini Hosp, Breast Unit, Carpi, Italy

[12] Azienda Osped Univ Policlin Modena, Dept Pathol, Modena, Italy

来源：

NPJ BREAST CANCER | 2021年 / 7卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT; THERAPY;

D O I：

10.1038/s41523-021-00223-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.

引用

页数：5

共 50 条

[31] Differential immune microenvironments in triple-negative breast cancer and hormone receptor-positive HER2-negative breast cancer: A spatial analysis via multiplex immunofluorescence
Cha, Yoon Jin
Park, Inho
Shin, Su-Jin
CANCER RESEARCH, 2024, 84 (06)
[32] Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer
Sestak, Ivana
Filipits, Martin
Buus, Richard
Rudas, Margaretha
Balic, Marija
Knauer, Michael
Kronenwett, Ralf
Fitzal, Florian
Cuzick, Jack
Gnant, Michael
Greil, Richard
Dowsett, Mitch
Dubsky, Peter
CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4682 - 4687
[33] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
Kovac, Anja
Kuhar, Cvetka Grasic
Ovcaricek, Tanja
Matos, Erika
Mencinger, Marina
Borstnar, Simona
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[34] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
Ma, S. J.
Oladeru, O. T.
Sood, A. J.
Mikucki, M.
Farrugia, M. K.
Singh, A. K.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
[35] A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
Harbeck, Nadia
Burstein, Harold J.
Hurvitz, Sara A.
Johnston, Stephen
Vidal, Gregory A.
CANCER, 2022, 128 : 2209 - 2223
[36] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
Frassoldati, Antonio
Biganzoli, Laura
Bordonaro, Roberto
Cinieri, Saverio
Conte, Pierfranco
De Laurentis, Michelino
Del Mastro, Lucia
Gori, Stefania
Lauria, Rossella
Marchetti, Paolo
Michelotti, Andrea
Montemurro, Filippo
Naso, Giuseppe
Pronzato, Paolo
Puglisi, Fabio
Tondini, Carlo Alberto
FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
[37] Effectiveness of platinum-based chemotherapy for hormone receptor-positive HER2-negative metastatic breast cancer
Uratani, Lucas Fernando
Bermejo, Francesco Sansone
Hashizume, Pedro HenriqueShimiti
Bonadio, Renata Colombo
Testa, Laura
CANCER RESEARCH, 2021, 81 (04)
[38] Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2-negative breast cancer
Kearney, Matthew R.
McGuinness, Julia E.
Kalinsky, Kevin
BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 1 - 13
[39] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
Torrisi, Rosalba
Marrazzo, Emilia
Agostinetto, Elisa
De Sanctis, Rita
Losurdo, Agnese
Masci, Giovanna
Tinterri, Corrado
Santoro, Armando
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
[40] Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Joo, Eun Hye
Kim, Sangmin
Park, Donghyun
Lee, Taeseob
Park, Woong-Yang
Han, Kyung Yeon
Lee, Jeong Eon
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)

← 1 2 3 4 5 →